Lazertinib and amivantamab in the treatment of lung cancer with EGFR mutation

Worldwide, the leading cause of mortality is lung cancer.There are two most common types of this cancer: non-small cell lung cancer (NSCLC), which is in first place in prevalence, and small cell lung cancer (SCLC).Lack of health screening and nonspecific symptoms are the leading causes of diagnosis in advanced or metastatic states.Late detection and resistance to therapy are the reasons why the prognosis remains poor.Lifestyle, environmental factors, and genetic mutations contribute to the development of lung cancer.The most common proto-oncogene in non-small cell lung cancer is EGFR.Upon mutation, it becomes an oncogene, which is a potential therapeutic target.This study aims to review the innovative guidelines for locally advanced or metastatic NSCLC with EGFR mutations.One of the wellknown third-generation EGFR tyrosine kinase inhibitors (TKIs) is Osimertinib.Unfortunately, it quickly developed resistance.There is a significant need to overcome resistance by combining lazertinib with amivantamab in both first-and second-line treatments.These drugs work through a different mechanism, allowing them to attack cancer cells from multiple angles.Studies like Mariposa, Mariposa-2, Papillon, Chrysalis, and Chrysalis-2 show new therapeutic options for patients with Locally Advanced or Metastatic NSCLC with EGFR Mutation (Ex20ins, ex19del, p.L858R).Furthermore, some studies show that reducing amivantamab's side effects and improving patient comfort can be achieved.There are two opinions: one is additional dexamethasone premedication, and the second is switching its administration from intravenous to subcutaneous.